Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28134449 | 1.00 | DTYMK (0.64) | DTYMKCA12CA1CA2CA7 | |
| SCHEMBL31283743 | 1.00 | DTYMK (0.64) | DTYMKCA12CA1CA2CA7 | |
| SCHEMBL10831554 | 0.98 | DTYMK (0.62) | DTYMKCA12CA1CA2CA7 | |
| SCHEMBL6397073 | 0.98 | DTYMK (0.62) | DTYMKCA12CA1CA2CA7 | |
| SCHEMBL1663582 | 0.85 | TSHR (0.53) | DTYMKCA12CA1CA2CA7 | |
| SCHEMBL4456465 | 0.83 | MAPT (0.52) | DTYMKCASP6BACE1NPSR1RXFP1 | |
| Potassium Ion SCHEMBL10831551 | 0.83 | BACE1 (0.49) | DTYMKCASP6BACE1NPSR1RXFP1 | |
| SCHEMBL11367351 | 0.83 | BACE1 (0.49) | DTYMKCASP6BACE1NPSR1RXFP1 | |
| SCHEMBL6397059 | 0.83 | BACE1 (0.49) | DTYMKCA1CA2CASP6BACE1 | |
| SCHEMBL11282911 | 0.82 | MEN1 (0.54) | DTYMKCASP6BACE1NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119286539-B | Liquid crystal aligning agent and method for preparing high-hardness polyimide liquid crystal alignment film by using same | 山东齐氟新材料有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119286539-A | Liquid crystal aligning agent and method for preparing high-hardness polyimide liquid crystal alignment film by using same | 山东齐氟新材料有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-114292305-A | Pharmaceutical co-crystal of progesterone and formic acid derivative and application thereof | 国家卫生健康委科学技术研究所 | 2022-04-08 | — | — | CN | claimed |
| US-10626141-B2 | Method for specific cleavage of C alpha-C bond and side chain of protein and peptide, and method for determining amino acid sequence | SHIMADZU CORPORATION (JP) | 2020-04-21 | — | — | US | claimed |
| EP-2483312-B1 | Antibodies that specifically bind to the EphA2 receptor | SANOFI SA (FR) | 2018-12-19 | — | — | EP | claimed |
| US-9932473-B2 | Encapsulating resin composition, semiconductor device using the encapsulating resin composition, and method for manufacturing semiconductor device using the encapsulating resin composition | PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) | 2018-04-03 | — | — | US | claimed |
| EP-3246706-A1 | METHOD FOR SPECIFIC CLEAVAGE OF C(ALPHA)-C BOND AND SIDE CHAIN OF PROTEIN AND PEPTIDE, AND METHOD FOR DETERMINING AMINO ACID SEQUENCE | Shimadzu Corporation (JP) | 2017-11-22 | — | — | EP | claimed |
| US-20170327533-A1 | METHOD FOR SPECIFIC CLEAVAGE OF C Alpha-C BOND AND SIDE CHAIN OF PROTEIN AND PEPTIDE, AND METHOD FOR DETERMINING AMINO ACID SEQUENCE | SHIMADZU CORPORATION (JP) | 2017-11-16 | — | — | US | claimed |
| EP-1390370-B1 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | IMMUNOGEN INC (US) | 2016-04-13 | — | — | EP | claimed |
| US-20150044197-A1 | ANTIBODIES THAT SPECIFICALLY BIND TO THE EPHA2 RECEPTOR | SANOFI (FR) | 2015-02-12 | — | — | US | claimed |
| EP-1390370-A4 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | IMMUNOGEN INC (US) | 2005-07-06 | — | — | EP | claimed |
| EP-1390370-A1 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | Immunogen, Inc. (US) | 2004-02-25 | — | — | EP | claimed |
| US-20030055226-A1 | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents | IMMUNOGEN, INC. | 2003-03-20 | — | — | US | claimed |
| WO-2002098883-A1 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | IMMUNOGEN, INC. (US) | 2002-12-12 | — | — | WO | claimed |
| US-6441163-B1 | COUPLING MAYTANSINOIDS HAVING DISULFIDE LINKER BEARING REACTIVE MOIETY TO SUCH AS ANTIBODIES WITHOUT PRIOR MODIFICATION OF SAID ANTIBODY; ONE-STEP, HIGH YIELD, LOWER COST | IMMUNOGEN, INC. | 2002-08-27 | — | — | US | claimed |
| EP-0304248-B1 | CARBON DIOXIDE SENSOR | Pfizer Hospital Products Group, Inc. (US) | 1992-11-19 | — | — | EP | claimed |
| US-4851195-A | FOR DETERMINING LIQUID PARTIAL PRESSURE; CONTAINING AN ABSORBER, A FLUORESCER AND BICARBONATE | PFIZER HOSPITAL PRODUCTS GROUP, INC. (US) | 1989-07-25 | — | — | US | claimed |
| EP-0024259-B1 | DERIVATIVES OF 5-(PYRIDYL-2-OXY)-2-NITROBENZOIC ACID, THEIR PREPARATION AND HERBICIDAL COMPOSITIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1985-07-31 | — | — | EP | claimed |
| US-4469893-A | Method for the preparation of nitrodiphenyl ethers | OCCIDENTAL CHEMICAL CORPORATION (US) | 1984-09-04 | — | — | US | claimed |
| EP-0024259-A1 | Derivatives of 5-(pyridyl-2-oxy)-2-nitrobenzoic acid, their preparation and herbicidal compositions containing them | CIBA-GEIGY AG (CH) | 1981-02-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055226-A1 | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents | SPR, SELPLG, CD2BP2 | DTYMK 565/4885CA12 728/4885CA1 1152/4885 |
| US-20170327533-A1 | METHOD FOR SPECIFIC CLEAVAGE OF C Alpha-C BOND AND SIDE CHAIN OF PROTEIN AND PEPTIDE, AND METHOD FOR DETERMINING AMINO ACID SEQUENCE | CPN1, CYBA, CRYAB | DTYMK 3140/4885CA12 212/4885CA1 115/4885 |
| US-10626141-B2 | Method for specific cleavage of C alpha-C bond and side chain of protein and peptide, and method for determining amino acid sequence | CPN1, CYBA, CRYAB | DTYMK 3140/4885CA12 212/4885CA1 115/4885 |
| US-20150044197-A1 | ANTIBODIES THAT SPECIFICALLY BIND TO THE EPHA2 RECEPTOR | EPHA2, CD2BP2, EPHB2 | DTYMK 2141/4885CA12 829/4885CA1 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.